semax
asset
Involved in
- FDA staff said their review of research found insufficient evidence to support semax’s use for the conditions in question.
- The FDA advisory panel recommended that compounding pharmacies be allowed to manufacture the peptides epitalon and semax, and recommended against manufacturing emideltide.
- The vote on adding semax for migraines and neurological conditions was 8-5.
- Vociferous supporters of semax noted that there is more data on the drug because it is approved in Russia for clinical use.
Statements attributed to it
Nothing in the record is attributed to this entity as a speaker.
Origin: first recognised while reading FDA advisory panel narrowly rejects compounding of one peptide, backs two others · 2026-09-11 07:34